Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)
Back to Freepaper Session

Early clinical outcomes of hole posterior chamber phakic introcular lens: an Asian perspective

Session Details

Session Title: Phakic IOL Implantation II

Session Date/Time: Wednesday 09/10/2013 | 08:00-10:30

Paper Time: 09:52

Venue: E104-105 (First Floor)

First Author: : A.Chuah MALAYSIA

Co Author(s): :                  

Abstract Details

Purpose:

To compare and evaluate the post-operative outcomes between hole ICL with CentraFLOW technology (ICL V4c) and Conventional ICL (ICL V4b) for refractive error correction in Asian eyes.

Setting:

Single site study, single surgeon at VISTA Eye Specialist, Malaysia.

Methods:

Post-operative outcomes of 30 eyes with V4c were compared with the results of 30 eyes with V4b. Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, intraocular pressure, higher order aberration and adverse events were evaluated at one week, one month and three month after surgery.

Results:

The preoperative mean spherical equivalent was -7.51 ± 2.80D for V4c eyes and -9.54 ± 2.05D for V4b eyes. All implantations were uneventful. At 3 month, the post-op mean spherical equivalent was -0.06 ± 0.21D for V4c eyes and -0.05 ± 0.17D for V4b eyes. The post-op mean intra-ocular pressure was 14.9 ± 3.6mmHg for V4c eyes and 14.1 ± 2.4mmHg for V4b eyes. At 3 month, 93.3% of the V4c eyes and 90% of the V4b eyes had 6/6 uncorrected visual acuity. All eyes achieved uncorrected visual acuity of 6/9 or better. No vision-threatening complications occurred.

Conclusions:

ICL V4c implantation has comparable post-operative result with V4b implantation even without iridectomy in Asian eyes. ICL V4c with the presence of central hole at the optic of ICL lens allow adequate aqueous flow without compromising patientÂ’s visual acuity and quality, suggesting its viability as a surgical option for the treatment of myopia or compound myopia astigmatism. Financial Disclosure: I do not have any invested interest in STAAR Surgical.

Financial Interest:

NONE


loading Please wait while information is loading.